<DOC>
	<DOCNO>NCT00077051</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Radiosensitizing drug , cytochlor tetrahydrouridine , may make tumor cell sensitive radiation therapy . Drugs use chemotherapy , cisplatin work different way stop growth tumor cell , either kill cell stop dividing . Combining radiosensitizers chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose cytochlor give together tetrahydrouridine , cisplatin radiation therapy treat patient advance squamous cell carcinoma oral cavity ( mouth ) oropharynx ( throat ) .</brief_summary>
	<brief_title>Cytochlor Tetrahydrouridine Radiosensitizers Cisplatin Combined With Radiation Therapy Treating Patients With Advanced Squamous Cell Carcinoma Oral Cavity ( Mouth ) Oropharynx ( Throat )</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose range cytochlor use phase II trial , base safety , toxicity , tissue selectivity , patient advance squamous cell carcinoma oral cavity oropharynx . - Determine safety toxicity profile cytochlor , tetrahydrouridine , concurrent radiotherapy follow radiotherapy alone patient . - Determine percentage cancer cell vs normal cell incorporate cytochlor DNA patient treat regimen . - Determine percentage replacement thymine 5-chlorouracil tumor vs normal tissue patient treat regimen . Secondary - Determine tissue selectivity regimen patient . - Determine level cytochlor metabolite within serum urine patient combination treatment radiotherapy alone initiate . - Determine pharmacokinetics regimen patient . OUTLINE : This open-label , dose-escalation study cytochlor . Patients receive tetrahydrouridine IV 5 minute follow cytochlor IV 3 day week 1 5 day week week 2-4 cisplatin IV 30-60 minute week 2 5 . Patients also undergo radiotherapy 5 day week week 2-7 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cytochlor maximum tolerate dose ( MTD ) determine . The MTD define dose 1 3 3 6 patient experience dose-limiting toxicity . Patients follow 1 month , monthly 3 month , every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 3-18 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tetrahydrouridine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma oral cavity oropharynx Stage III disease eligible surgery Stage IV disease allow patient eligible chemotherapy refuse chemotherapy No distant metastasis Previously untreated disease No osteoradionecrosis patient tumor involve maxilla Tumor tissue/normal adjacent tissue ( T/N ) ratio dC kinase dCMP deaminase great 2.5 PATIENT CHARACTERISTICS : Age Over 21 Performance status Karnofsky 80100 % OR ECOG 01 Life expectancy More 6 month Hematopoietic Absolute neutrophil count great 1,500/mm^3 WBC least 3,000/mm^3 Platelet count great 100,000/mm^3 Hepatic AST/ALT less 2.5 time upper limit normal Bilirubin normal Renal Creatinine normal OR Creatinine clearance great 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No impend carotid rupture Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study treatment HIV negative No concurrent uncontrolled illness No active ongoing infection No alcohol dependence No psychiatric illness social situation would preclude study compliance No malignancy within past 3 year except lowrisk , nonmelanomatous skin cancer , carcinoma situ ( e.g. , breast , cervix , bladder ) , stage T12 , lowtomoderate grade prostate cancer ( Gleason score great 7 ) PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy except contraceptive replacement steroid Radiotherapy Not specify Surgery See Disease Characteristics Other No prior therapy head neck cancer No concurrent experimental medication No concurrent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
</DOC>